Anebulo Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is developing treatments for cannabis-induced toxicity, such as acute cannabis-induced toxicity in children, acute cannabinoid intoxication (ACI) in adults, and the landscape of acute cannabis-induced conditions. Its lead product candidate, selonabant (formerly ANEB-001), has completed a Phase II clinical trial evaluating its utility in blocking and reversing the negative effects of ACI in healthy adults challenged with oral tetrahydrocannabinol. Selonabant is orally bioavailable, absorbed, and has also been formulated for intravenous administration. Selonabant is intended to reverse the negative effects of cannabis-induced toxicity and reduce time to recovery. It is also focused on the advancement of a selonabant IV formulation as a potential treatment for pediatric patients with acute cannabis-induced toxicity. Selonabant is a competitive antagonist at the human cannabinoid receptor type-1 receptor.